Suppr超能文献

新辅助放化疗对食管癌分析淋巴结数量和大小的影响。

Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.

机构信息

Department of General, Visceral, and Cancer Surgery, University of Cologne, Cologne, Germany.

出版信息

Ann Surg Oncol. 2010 Dec;17(12):3187-94. doi: 10.1245/s10434-010-1196-8. Epub 2010 Jun 29.

Abstract

BACKGROUND

Studies have shown that along with primary tumor response, lymph node status after RTx/CTx is one of the most important prognostic factors for advanced esophageal carcinoma. The goal of our study was to investigate the influence of neoadjuvant radiochemotherapy (RTx/CTx) on lymph nodes (LN).

MATERIALS AND METHODS

From 1997 until 2006, 297 patients underwent surgery for advanced esophageal carcinoma. Of these, 192 received preoperative chemoradiation (5-FU, cisplatin, 36 Gy). The following matched subgroups were chosen: Group I, 20 with surgery alone: 10 adenocarcinoma (AC), 10 squamous cell carcinoma (SCC); Group II, 20 with minor response (10 AC, 10 SCC); Group III, 20 with major response (10 AC, 10 SCC). Tumor response was graded as "minor" or "major" according to the Cologne Regression Scale, the LN size determined by the largest measured diameter.

RESULTS

A total of 1967 LNs from 60 patients were examined. Of these, 161 LNs showed metastasis. The median number of LNs examined per patient was not significantly higher in group I compared with the group with pretreatment (32 vs 31). Group I and group II showed LN metastasis (LNM) in 65% of cases, and group III in only 20% (p = 0.011). LNMs after pretreatment had significantly smaller median diameters (5.0 mm) than those without (7.0 mm) (p < 0.02). Nonmetastatic LN size did not vary between the three groups. LN size with and without metastasis did not differ between AC and SCC or between major and minor responders.

CONCLUSION

With good response to neoadjuvant radiochemotherapy, the size and the number of metastatic LNs is significantly reduced regardless of histologic cancer type.

摘要

背景

研究表明,除了原发肿瘤的反应外,放射治疗/化疗后淋巴结状态是晚期食管癌最重要的预后因素之一。我们的研究目的是研究新辅助放化疗(RTx/CTx)对淋巴结(LN)的影响。

材料和方法

1997 年至 2006 年,297 例患者因晚期食管癌接受手术治疗。其中 192 例接受术前放化疗(5-FU、顺铂、36 Gy)。选择以下匹配亚组:I 组 20 例,单独手术:10 例腺癌(AC),10 例鳞癌(SCC);II 组 20 例,轻度反应(10 例 AC,10 例 SCC);III 组 20 例,主要反应(10 例 AC,10 例 SCC)。根据科隆回归量表,肿瘤反应分为“轻度”或“重度”,LN 大小由最大测量直径确定。

结果

共检查了 60 例患者的 1967 个 LN。其中,161 个 LN 有转移。与术前组相比,I 组患者检查的 LN 中位数无显著升高(32 对 31)。I 组和 II 组有 65%的病例发生 LN 转移(LNM),而 III 组只有 20%(p = 0.011)。预处理后 LNM 的中位数直径(5.0mm)明显小于无 LNM 的直径(7.0mm)(p < 0.02)。三组间无转移的 LN 大小无差异。有转移和无转移的 LN 大小在 AC 和 SCC 之间或在主要和次要反应者之间无差异。

结论

新辅助放化疗反应良好时,无论组织学癌类型如何,转移性 LN 的大小和数量都会显著减少。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验